License Agreement for RescueFlow in the Nordic countries

License Agreement for RescueFlow® in the Nordic countries BioPhausia has signed a Letter of Intent with Pharmalink Basläkemedel, covering rights to market BioPhausia's product RescueFlow® in the Nordic region. Pharmalink is paying a one-time fee, plus a royalty of 15% on sales. RescueFlow® is especially designed for the initial treatment of blood loss due to trauma. The primary characteristics are a rapid onset and a good duration of the volume expandary effect. RescueFlow® will have a price in excess of SEK 700 per unit of 250 ml. Negotiations are under way with another party covering rights to market RescueFlow® in other parts of the world. Comment by Erika Kjellberg Eriksson, President of BioPhausia: "The approval of RescueFlow® in Sweden was a breakthrough for the company. Using the procedure for mutual recognition of product approvals, we are presently aiming to obtain approval for RescueFlow® in Europe. We expect to have other marketing authorizations during the late spring. The agreement with Pharmalink for the Nordic region is the first step in the commercialization of products and projects." Comment by Mikael Bender, President of Pharmalink: "With RescueFlow® we are gaining access to a completely new type of specialty pharmaceutical, a product that supplements our existing line very well. Preparations for the launching will start within days and RescueFlow® will begin to be sold within a couple of months." Uppsala. February 4, 1999 Based on its contact network and know-how, primarily in connective tissue biology, BioPhausia is developing products for licensing to well-established pharmaceutical companies with strong marketing organizations. The product and project portfolio includes RescueFlow®, a resuscitation solution, Krillase® for the debridement of chronic wounds (clinical phase III), and preclinical projects in the tumor and trauma treatment areas. Information on RescueFlow® is available on BioPhausia's home page on the World Wide Web: www.biophausia.se For additional information on BioPhausia, please call: Erika Kjellberg Eriksson, President. Tel.: +46 (0)18-34 99 00. Pharmalink develops, produces and markets drugs used in renal care and replacement of fluids. The company markets its products throughout the world, with special emphasis on the Nordic region. Sales in 1998 amounted to SEK 110 M. For additional information on Pharmalink, please call: Mikael Bender, President. Tel.: +46 (0)8-587 718 00. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/02/04/19990204BIT00440/bit0001.doc http://www.bit.se/bitonline/1999/02/04/19990204BIT00440/bit0002.pdf